As the year 2021 ended, Aagami got a licensing term sheet signed for its client.Other details are confidential until press release by the client and i...
Published : 31 Dec 2021
Read MoreAagami are proud to announce that their Current Japanese client has given a new assignment, to seek partnerships for their other assets in the pipelin...
Published : 27 Dec 2021
Read MoreAfter a long wait due to the pandemic, in-person conferences and meetings are open again. Aagami CEO Dinesh Jain will attend Biotech Showcase and...
Published : 10 Dec 2021
Read MoreAagami successfully delivered an IP Audit Analysis & Valuation report to their European Client. Aagami executes and delivers such projec...
Published : 15 Nov 2021
Read MoreThe month of October brought another contract extension for Aagami. This time from US client developing First-in-Class Non-Opioid Analgesic for P...
Published : 11 Oct 2021
Read MoreAnother month, and another contract extension. Our Japanese client has extended their contract with Aagami as they have been very satisfied. Aagami ha...
Published : 20 Sep 2021
Read MoreAagami’s French biotech client developing a blockbuster potential smoking cessation drug has extended contract with Aagami based on progress and ter...
Published : 10 Sep 2021
Read MoreAvisa Myko Inc. (Alumnus of IndieBio accelerator, San Francisco) has developed a precision fermentation-based technology to produce Natural Soluble Me...
Published : 05 Aug 2021
Read MoreA Pennsylvania Biopharma Therapeutics company (Subsidiary of a Biotech company from China) has appointed Aagami for supporting their out-licensing/co-...
Published : 15 Jul 2021
Read MoreA Swedish biotech company has chosen Aagami to support them for Partnering including Investment, Licensing, Co-development, and other forms for their ...
Published : 11 Jun 2021
Read More